Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

Memorial Sloan Kettering Cancer Center, New York

American Oncology Partners, P.A., Bethesda

Prisma Health Cancer Institute, Greenville

Mid-Florida Hematology & Oncology Centers, Orange City

Nashville Oncology Associates, PC, Nashville

Horizon Oncology Research, Inc., Lafayette

Henry Ford Health System, Detroit

St. Vincent Frontier Cancer Center, Billings

Site #120, Dallas

Site #114, Houston

UCLA Dept. of Medicine - Hematology/Oncology, Los Angeles

Beverly Hills Cancer Center, Beverly Hills

Oregon Health & Science University, Portland

MultiCare Regional Cancer Center, Tacoma

Eastern Connecticut Hematology & Oncology Associates, Norwich

Tufts Medical Center, Boston

Englewood Hospital and Medical Center, Englewood

Site #115, Hackensack

Yokohama City University Medical Center, Yokohama

Kurashiki Central Hospital, Kurashiki-shi

NHO Kyushu Cancer Center, Fukuoka

Gifu University Hospital, Gifu

Kagawa University Hospital, Kita-gun

Kitakyushubyoin Kitakyusyu General Hospital, Kitakyushu-shi

Kumpukai Sano Hospital, Kobe

NHO Shikoku Cancer Center, Matsuyama

Kochi Medical School Hospital, Nankoku-shi

NHO Osaka National Hospital, Osaka

Osaka General Medical Center, Osaka

Tonan Hospital, Sapporo

Shizuoka Cancer Center, Sunto-gun

University of Tsukuba Hospital, Tsukuba